Intervention
Tadalafil
ClinicalTrials.gov intervention label
Explore related research
Search across original and mapped recordsSearch results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 34 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
34 shownCOMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular ComorbiditiesNCT07245680 · 2026-04-28
RECRUITINGComparison of Sequential to Initial Combination Therapy in PAHNCT06968962 · 2025-05-14
RECRUITINGBreathe Easier With Tadalafil Therapy for Dyspnea in COPD-PHNCT05937854 · 2024-04-01
RECRUITINGTadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary DiseaseNCT05844462 · 2024-02-01
RECRUITINGUltrasonic Enhancement Delivery of Phosphodiesterase Inhibitors Nanoparticles for Diabetic Management of the FootNCT07690566 · 2025-09-01
COMPLETEDAcute Haemodynamic Study of TPN171H in Patients with Pulmonary Arterial HypertensionNCT04483115 · 2020-11-16
COMPLETEDTadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck CancerNCT03993353 · 2020-04-07
COMPLETEDRiociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapyNCT02891850 · 2017-01-11
COMPLETEDPDE5 Inhibition for Obesity-Related Cardiometabolic DysfunctionNCT02819440 · 2016-07-01
COMPLETEDThe Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial HypertensionNCT02558231 · 2016-05-01
COMPLETEDEffects on Insulin Resistance With Tadalafil in Type 2 Diabetes - a Double-blind, Placebo-controlled Crossover StudyNCT02601989 · 2015-11-01
COMPLETEDEffect of Tadalafil on Insulin Secretion and Insulin Sensitivity in Obese Men.NCT02595684 · 2015-08-01
COMPLETEDDaily Tadalafil on Body Fat and Lean MassNCT02554045 · 2015-01-01
COMPLETEDSagene 2014 - Parkinson's Disease and Erectile DysfunctionNCT02225548 · 2014-09-01
UNKNOWNA Study of LY2623091 in Participants With High Blood PressureNCT02194465 · 2014-08-01
COMPLETEDREmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrsNCT01803828 · 2014-05-01
COMPLETEDA Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)NCT01824290 · 2014-02-05
COMPLETEDPhosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart FailureNCT01910389 · 2013-11-01
TERMINATEDPhosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal DamageNCT01960153 · 2013-10-01
WITHDRAWNTadalafil for Pulmonary Hypertension Due to Chronic Lung DiseaseNCT01862536 · 2013-10-01
COMPLETEDAortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot StudyNCT01275339 · 2012-12-01
TERMINATEDTadalafil and Nesiritide as Therapy in Pre-clinical Heart FailureNCT01544998 · 2012-02-01
COMPLETEDA Trial of Tadalafil and Glycemic TraitsNCT01444651 · 2011-08-01
COMPLETEDTadalafil for Sarcoidosis Associated Pulmonary HypertensionNCT01324999 · 2011-03-01
COMPLETEDTreprostinil Combined With Tadalafil for Pulmonary HypertensionNCT01302444 · 2011-03-01
TERMINATEDAortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot StudyNCT01272388 · 2011-01-01
TERMINATEDTadalafil Effects in Left Ventricle Diastolic Dysfunction in Resistant Hypertensive PatientsNCT01743911 · 2010-09-01
COMPLETEDDo Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?NCT01197469 · 2010-09-01
COMPLETEDTadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation TherapyNCT00931528 · 2009-11-01
COMPLETEDEffects of PDE-5 Inhibition on Postprandial Hyperglycemia in Type 2 DiabetesNCT01238224 · 2009-11-01
TERMINATEDLong Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids.NCT00705588 · 2008-08-01
UNKNOWNStudy of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)NCT00617305 · 2008-04-01
COMPLETEDEffect of Tadalafil in Chronic Obstructive Lung Disease Patients Suffering From Secondary Pulmonary HypertensionNCT00506701 · 2008-02-01
WITHDRAWNAssessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or HyperlipidemiaNCT00668109 · 2003-12-01
COMPLETEDCommon conditions
Pulmonary Hypertension7Pulmonary Arterial Hypertension6Chronic Obstructive Pulmonary Disease3Obesity3Aortic Stenosis2Erectile Dysfunction2Heart Failure2Pulmonary Arterial Hypertension (PAH)2Sexual Dysfunction2Amputation1Cancer1Cancer of Esophagus1Cancer of Head and Neck1Cancer of Mouth1Cancer of Neck1Cancer, Metastatic1Cardiovascular Disease1Cardiovascular Disease (CVD)1Chronic Obstructive Lung Disease1Chronic Obstructive Pulmonary Disease (COPD)1Comorbidities1Congestive Heart Failure1Diabete Mellitus1Diabetes Mellitus Type 21Diabetes Mellitus, Type 21
Mapped diseases appearing in these trials
Shared study participation does not establish that this intervention treats a disease.
pulmonary hypertension8pulmonary arterial hypertension6chronic obstructive pulmonary disease5obesity disorder3type 2 diabetes mellitus3aortic valve stenosis2cardiovascular disorder2erectile dysfunction2heart failure2cancer1congestive heart failure1esophageal cancer1essential hypertension1glucose intolerance1head and neck cancer1head and neck carcinoma1head and neck squamous cell carcinoma1malignant tumor of neck1metastatic malignant neoplasm1Parkinson disease1
Leading sponsors
Assistance Publique - Hôpitaux de Paris
2
Bayer
2
Eli Lilly and Company
2
University of Roma La Sapienza
2
VA Office of Research and Development
2
Washington University School of Medicine
2
Actelion
1
Carelon Research
1
Deraya University
1
Gilead Sciences
1
Göteborg University
1
Herlev Hospital
1
Massachusetts General Hospital
1
Mayo Clinic
1
Rabin Medical Center
1
Trial status mix
COMPLETED21
TERMINATED5
RECRUITING4
UNKNOWN2
WITHDRAWN2
Phase mix
PHASE210
PHASE310
PHASE410
NA4
PHASE12
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.